Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Lung Neoplasms

Carcinoma

Prostatic Neoplasms

Neuroendocrine Tumors

Small Cell Lung Carcinoma

Carcinoma, Neuroendocrine

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Small Cell Lung Cancer

Neuroepithelioma

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Antibodies, Monoclonal

Atezolizumab

Immunoglobulins

Immunoglobulins, Intravenous

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

HPN328 will be administered as a single agent once weekly via IV infusion during each 21 day cycle.

HPN328 will be administered as a single agent, via IV infusion either once every 2 weeks (28-day cycle), or once every 3 weeks (21-day cycle).

SCLC patients will be treated with a combination regimen of HPN328 and atezolizumab. HPN328 will be administered once every 2 weeks via IV infusion during each 28-day cycle. Atezolizumab will be administered once every 4 weeks via IV infusion on Day 1 of each 28-day cycle.

HPN328 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct \[TriTAC®\]) containing 3 humanized antibody derived binding domains

HPN328

Atezolizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody which potently and selectively inhibits binding of programmed death receptor 1 ligand (PD-L1) on tumor cells and tumor infiltrating immune cells in the tumor microenvironment

Harpoon ClinicalTrials.gov Contact

Garrett Crook

Kanya Sankar, MD

Christopher De Leon

Emma Filar

Erin Schenk, MD

Himisha Beltran, MD

Aaron Le

Hirva Mamdani, MD

Janine Miller

Prantesh Jain, MD

Alissa Cooper, MD

Cancer Information Services

Afshin Dowlati, MD

Rachel Sanborn, MD

Tennessee Oncology Sarah Cannon Research Institute

Melissa L. Johnson, MD

Jonathan Thompson, MD

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3)

Study in Patients With Advanced Cancers Associated With Expression of DLL3

* Single dose - maximum concentration, time to maximum concentration, area under the single dose concentration-time curve over the dosing interval, area under the concentration-time curve extrapolated to infinity, terminal elimination half-life, and clearance as data permit
* Multiple dose (assuming stead state is achieved) - maximum concentration at steady state, time to maximum concentration, area under the steady state concentration-time curve over dosing interval, terminal elimination half-life, minimum concentration, clearance, volume of distribution, and accumulation ratio as data permit.

Harpoon Therapeutics

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study in Patients With Advanced Cancers Associated With Expression of DLL3	NCT04471727	Small-Cell Lung... Neuroendocrine ...	HPN328 Atezolizumab	18 Years - 100 Years	Harpoon Therapeutics
Study in Patients With Advanced Cancers Associated With Expression of DLL3	NCT04471727	Small-Cell Lung... Neuroendocrine ...	HPN328 Atezolizumab	18 Years - 100 Years	Harpoon Therapeutics

Spots Global Cancer Trial Database for delta like canonical notch ligand 3